Vor Biopharma (NASDAQ:VOR) Shares Up 8% – Still a Buy?

Vor Biopharma Inc. (NASDAQ:VOR)’s stock price shot up 8% on Friday . The stock traded as high as $15.76 and last traded at $16.1260. 188,694 shares changed hands during mid-day trading, a decline of 81% from the average session volume of 975,209 shares. The stock had previously closed at $14.93.

Analyst Upgrades and Downgrades

Several brokerages recently commented on VOR. Jefferies Financial Group raised Vor Biopharma to a “strong-buy” rating in a research note on Thursday, April 30th. Wedbush upped their price objective on Vor Biopharma from $15.00 to $18.00 and gave the stock a “neutral” rating in a research report on Thursday, May 14th. Wells Fargo & Company started coverage on Vor Biopharma in a report on Thursday, March 19th. They set an “overweight” rating and a $30.00 price objective for the company. Wall Street Zen cut shares of Vor Biopharma from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Finally, HC Wainwright reiterated a “buy” rating and issued a $31.00 price target on shares of Vor Biopharma in a research note on Monday, May 18th. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $42.25.

Vor Biopharma Price Performance

The stock has a 50 day simple moving average of $14.76 and a two-hundred day simple moving average of $14.36.

Vor Biopharma (NASDAQ:VOR) last announced its quarterly earnings data on Monday, March 30th. The company reported $307.61 earnings per share (EPS) for the quarter. On average, equities research analysts predict that Vor Biopharma Inc. will post -2.51 EPS for the current year.

Insider Transactions at Vor Biopharma

In related news, Director Ra Capital Management, L.P. sold 165,150 shares of Vor Biopharma stock in a transaction dated Wednesday, April 22nd. The stock was sold at an average price of $15.77, for a total transaction of $2,604,415.50. Following the completion of the transaction, the director owned 2,402,095 shares in the company, valued at approximately $37,881,038.15. This trade represents a 6.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In the last three months, insiders have sold 3,002,903 shares of company stock valued at $49,412,176. Company insiders own 0.27% of the company’s stock.

Hedge Funds Weigh In On Vor Biopharma

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Vor Biopharma during the 4th quarter worth about $36,000. Goldman Sachs Group Inc. grew its position in Vor Biopharma by 218.2% during the first quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock worth $61,000 after buying an additional 58,247 shares in the last quarter. XTX Topco Ltd acquired a new stake in shares of Vor Biopharma during the 2nd quarter worth $66,000. Chung Wu Investment Group LLC acquired a new stake in Vor Biopharma during the fourth quarter worth about $109,000. Finally, Susquehanna Portfolio Strategies LLC bought a new position in Vor Biopharma in the fourth quarter valued at approximately $134,000. 97.29% of the stock is owned by institutional investors.

Vor Biopharma Company Profile

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).